AI assistant
Sending…
MYRIAD GENETICS INC — Director's Dealing 2018
Aug 3, 2018
32566_dirs_2018-08-03_d45a94dd-b87d-4b5c-b540-f91a39d4e60f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2018-08-01
Reporting Person: Sanders Walter Lloyd (President Myriad Oncology)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 24961 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Incentive Stock Option (right to buy) | $26.49 | 2021-09-17 | Common Stock (3775) | Direct | |
| Incentive Stock Option (right to buy) | $27.07 | 2022-09-12 | Common Stock (3694) | Direct | |
| Non-Qualified Stock Option (right to buy) | $26.49 | 2021-09-17 | Common Stock (16850) | Direct | |
| Non-Qualified Stock Option (right to buy) | $27.07 | 2022-09-12 | Common Stock (5056) | Direct |
More from MYRIAD GENETICS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 5
Annual Report
2026
Apr 14
Proxy Solicitation & Information Statement
2026
Apr 14
Proxy Solicitation & Information Statement
2026
Apr 14
Major Shareholding Notification
2026
Apr 7
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 5
Regulatory Filings
2026
Mar 4
Director's Dealing
2026
Mar 2